Press Releases
 
MDD, Anxiety and Panic Disorder Therapeutics Market Trends and Growth Factors Analysis 2014 - 2020

, 17 April 2019 -- MDD, Anxiety and Panic Disorder Therapeutics Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020

Epidemiologic studies have concluded that majority of the individuals experiencing panic attack will also experience a major depression disorder (MDD) and this factor increases the possibility of co-occurrence of panic disorder. These disorders tend in functional disability along with suicidal behavior in the patients and are in association with depression and panic conditions.

Anxiety symptoms include obsessive, obtrusive, worried thoughts, irritability, confusion and difficulty concentrating and frustration. Person with anxiety also feel uncomfortable physical sensations, tense some characteristics such as trembling, a racing heartbeat, sweating, difficulty breathing and nausea. The sudden onset of such symptoms is often an indicator of a severe panic attack. Anxiety can also lead to lightheadedness, headaches, digestive problems and insomnia.

Obtain Report Details @ https://www.transparencymarketresearch.com/mdd-anxiety-panic-disorder-therapeutics.html

According to National Comorbidity Survey Replication, the prevalence for an anxiety disorder was about 18%, and for mood disorder it was 9.5% every year. Lifetime prevalence for any anxiety disorder and MDD were approximately 29% and 16.6%, respectively. Assuming a 50% comorbidity rate, between 5% and 9% of the ##### population has comorbid depression-anxiety in a year’s time. The treatment against these comorbid depression and anxiety disorder are cognitive-behavioral therapy (CBT) as an effective psychological treatment but it needs support from therapeutic drugs where anti-depressants are observed to be the first-line of treatment for comorbid depression and anxiety disorders.

But in this disorder the anti-depressants may turn into panic attacks for patients when they have undetected bipolar disorder which should be analyzed by mapping the family history of patient before treatment. According to World Health Organization (WHO), neuropsychiatric disorders accounted for more than 13% of all medical disability worldwide and for more than 27% of all noncommunicable disease in 2005. Depression alone produced 10% to 12% of all disability from noncommunicable disease and approximately 5% of all disability (noncommunicable, communicable, injury). Thus, comorbid anxiety and depression may account for as much as 2% to 4% of all medical disability worldwide.

Request Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=2928

The antidepressants particularly used in this treatment are serotonin-specific reuptake inhibitor (SSRI) such as escitalopram, citalopram, fluvoxamine, paroxetine, fluoxetine, sertraline and Serotonin-norepinephrine reuptake inhibitors (SNRI) is venlafaxine that are observed to be the first-line pharmacotherapy for depression and anxiety disorders.

The recent updates regarding major depression disorder (MDD), anxiety and panic disorder market is about to go through a vibrant phase with forthcoming patent expiries for leading products such as BMS/Otsuka’s Abilify and Eli Lilly\’s Cymbalta, and in January 2014 the recent launch of, Lundbeck/Takeda\’s Brintellix a multimodal antidepressant.

The other devices present in the pipeline are Richter/Mitsubishi Tanabe Pharma’s cariprazine, Naurex’s GLYX-13, Forest (Actavis)/Gedeon and Alkermes’s ALKS-5461 along with antidepressant therapies such as Lundbeck/Takeda’s tedatioxetine, e-Therapeutics’ ETS6103 and Euthymics Bioscience’s amitifadine. The overall major depression disorder (MDD), anxiety and panic disorder market is about to observe a significant growth in the market. As the drivers impacting this market are primarily increasing the amount of stress and lack of sleep in ##### population that are having various psychological problems.

Request for TOC @ https://www.transparencymarketresearch.com/sample/sample.php?flag=T&rep_id=2928

Some of the key players in the Major Depression Disorder (MDD), anxiety and panic disorder market are Shire Plc, Forest Laboratories, Novartis AG, Astra Zeneca Plc, Eli Lilly and Company, Pfizer, Inc., Janssen Pharmaceuticals, Inc. (JPI), BTG International (BTG), H. Lundbeck A/S, Alexza Pharmaceuticals and others.

# # #


Submitted by hawer on Wednesday, 17 April 2019 at 10:02 PM
Category: Health Care & Medical
 
Related News

Phototherapy Equipment Market - Growing Uptake of CFL to Boost Market Growth
Thursday, 20 Jun 2019

Healthcare Automation Market: Rising Clinical Research Activities to Bolster the Demand of the Marke
Thursday, 20 Jun 2019

Cell Expansion Market - Key Players Keen on Tapping into the Opportunities in the Emerging Economies
Thursday, 20 Jun 2019

Marine Derived Drugs Market Developments, Growth and 2016 – 2024 Forecast Research Study
Wednesday, 19 Jun 2019

Autoimmune Treatment Market Key Report 2014 and Future Opportunity Assessment 2024
Wednesday, 19 Jun 2019

Related Events

2nd Journal of Thermal Analysis and Calorimetry Conference
Tuesday, 18 Jun 2019

Vestibular Schwannoma Conference 2019
Wednesday, 19 Jun 2019

Biomarkers And Diagnostics for Complex And Rare Diseases
Wednesday, 19 Jun 2019

2nd International Public Mental Health Conference
Wednesday, 19 Jun 2019

III World Congress and VI International Congress on Dual Disorders ICDD2019
Wednesday, 19 Jun 2019

Latest News

Phototherapy Equipment Market - Growing Uptake of CFL to Boost Market Growth
Thursday, 20 Jun 2019

Healthcare Automation Market: Rising Clinical Research Activities to Bolster the Demand of the Marke
Thursday, 20 Jun 2019

An Insight of common types of roofing systems
Thursday, 20 Jun 2019

Cell Expansion Market - Key Players Keen on Tapping into the Opportunities in the Emerging Economies
Thursday, 20 Jun 2019

Sex Dating Online - The Way to Hook With Ladies of All Ages
Wednesday, 19 Jun 2019

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Thursday, 20 June 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • ESPNIC 2019
  • Palo Alto Networks: Security Simplified - Enterprise Security Series
  • 2nd Journal of Thermal Analysis and Calorimetry Conference
  • EPHJ-EPMT-SMT Trade Show
  • Palo Alto Networks: May - Palo Alto Networks Heads-up

  • Latest Jobs
    Sorry, there are currently no entries posted here.